Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2013

01-06-2013 | Original Article

Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial

Authors: Hiroji Uemura, Masahiro Yanagisawa, Ichirou Ikeda, Kiyoshi Fujinami, Akira Iwasaki, Sumio Noguchi, Kazumi Noguchi, Yoshinobu Kubota, Yokohama Bone Metastasis Study Group

Published in: International Journal of Clinical Oncology | Issue 3/2013

Login to get access

Abstract

Background

To ascertain the anti-tumor effect of zoledronic acid (ZOL) treatment on clinical outcomes in patients with bone metastatic prostate cancer, we examined the effect of ZOL started simultaneously with hormonal therapy as initial treatment in these patients.

Methods

Forty-seven patients with bone-metastatic prostate cancer who received a luteinizing hormone releasing-hormone (LHRH) analogue and an anti-androgen [maximal androgen blockade (MAB)] were assigned to receive ZOL (4 mg intravenous administration every month for 2 years). The time to progression (TTP) of the prostate-specific antigen (PSA), the overall survival (OS), and the rate of PSA decrease in patients with MAB and ZOL treatment (ZOL group) were compared with these parameters in patients who received only MAB at one institute as a control group (non-ZOL group).

Results

Although the nadir PSA level and the rate of PSA normalization showed no significant differences between the ZOL and non-ZOL groups, the time to nadir PSA in the ZOL group was significantly shorter than that in the non-ZOL group (P < 0.05, Mann–Whitney U-test). There was a significant difference in TTP (P = 0.017, log-rank test) between the ZOL and non-ZOL groups, and statistically significant differences in TTP and OS between the ZOL and non-ZOL groups (P = 0.044 and 0.035, log-rank test) were recognized particularly in patients with advanced disease (extension of disease, grade 3 and 4).

Conclusions

Simultaneous administration of ZOL and MAB as initial treatment delayed TTP in bone-metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti-tumor activity to delay disease progression.
Appendix
Available only for authorised users
Literature
1.
Cooperberg MR, Hinotsu S, Namiki M et al (2009) Assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27:4306–4313PubMedCrossRef
2.
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240PubMedCrossRef
3.
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
4.
Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69PubMedCrossRef
5.
Demers LM (2003) Bone markers in the management of patients with skeletal metastases. Cancer 97(3 Suppl):874–879PubMedCrossRef
6.
Percival RC, Urwin GH, Harris S et al (1987) Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13:41–49PubMed
7.
Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRef
8.
Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432PubMedCrossRef
9.
Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691PubMedCrossRef
10.
Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188–2194PubMedCrossRef
11.
Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195–202PubMedCrossRef
12.
DePuy V, Anstrom KJ, Castel LD et al (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876PubMedCrossRef
13.
Yigitbasi O, Ozturk U, Goktug HN et al (2011) Prognostic factors in metastatic prostate cancer. Urol Oncol 29:162–165PubMedCrossRef
14.
Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedCrossRef
15.
Velde NV, Wu EQ, Guo A et al (2011) The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis 14:79–84PubMedCrossRef
16.
Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453–475PubMedCrossRef
17.
Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151PubMedCrossRef
18.
Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583PubMedCrossRef
19.
Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175–1181PubMedCrossRef
20.
Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001–1010PubMedCrossRef
21.
Coleman R, Cook R, Hirsh V et al (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11–23PubMedCrossRef
22.
Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13(15 Pt 1):4482–4486PubMedCrossRef
23.
Melisi D, Caputo R, Damiano V et al (2005) Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12:1051–1058PubMedCrossRef
24.
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA et al (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364–371PubMedCrossRef
Metadata
Title
Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial
Authors
Hiroji Uemura
Masahiro Yanagisawa
Ichirou Ikeda
Kiyoshi Fujinami
Akira Iwasaki
Sumio Noguchi
Kazumi Noguchi
Yoshinobu Kubota
Yokohama Bone Metastasis Study Group
Publication date
01-06-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0406-8

Other articles of this Issue 3/2013

International Journal of Clinical Oncology 3/2013 Go to the issue

Original Article

Prognostic significance of peritoneal lavage cytology in patients with colorectal cancer

Original Article

Treatment of bone metastases before the onset of pain

Letter to the Editor

Does long-term treatment with Doxil® predispose patients to oral cancer?

Original Article

High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma

Original Article

Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients

Original Article

Comparison of pirarubicin-based versus gemcitabine–docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits